CA3095682A1 - Use of gaboxadol in the treatment of substance use disorders - Google Patents

Use of gaboxadol in the treatment of substance use disorders Download PDF

Info

Publication number
CA3095682A1
CA3095682A1 CA3095682A CA3095682A CA3095682A1 CA 3095682 A1 CA3095682 A1 CA 3095682A1 CA 3095682 A CA3095682 A CA 3095682A CA 3095682 A CA3095682 A CA 3095682A CA 3095682 A1 CA3095682 A1 CA 3095682A1
Authority
CA
Canada
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
patient
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095682A
Other languages
English (en)
French (fr)
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CA3095682A1 publication Critical patent/CA3095682A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3095682A 2018-04-06 2019-04-06 Use of gaboxadol in the treatment of substance use disorders Pending CA3095682A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862653641P 2018-04-06 2018-04-06
US62/653,641 2018-04-06
US201862654786P 2018-04-09 2018-04-09
US62/654,786 2018-04-09
PCT/US2019/026218 WO2019195813A1 (en) 2018-04-06 2019-04-06 Use of gaboxadol in the treatment of substance use disorders

Publications (1)

Publication Number Publication Date
CA3095682A1 true CA3095682A1 (en) 2019-10-10

Family

ID=68101544

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095682A Pending CA3095682A1 (en) 2018-04-06 2019-04-06 Use of gaboxadol in the treatment of substance use disorders

Country Status (10)

Country Link
US (2) US20190321341A1 (https=)
EP (1) EP3761979A4 (https=)
JP (1) JP2021521103A (https=)
KR (1) KR20210039324A (https=)
CN (1) CN112601524A (https=)
AU (1) AU2019249277A1 (https=)
CA (1) CA3095682A1 (https=)
IL (1) IL277805A (https=)
MX (1) MX2020010545A (https=)
WO (1) WO2019195813A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IT1313585B1 (it) * 1999-07-30 2002-09-09 Neuroscienze S C A R L Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
CN101168056A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 混合物制剂
CN101168058A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 一种混合物制剂
CN101168057A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 多巴胺激动剂制剂
GB0810063D0 (en) * 2008-06-03 2008-07-09 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
MX2013002162A (es) * 2010-08-24 2013-04-05 Univ California Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina.

Also Published As

Publication number Publication date
EP3761979A4 (en) 2021-06-30
MX2020010545A (es) 2021-01-08
KR20210039324A (ko) 2021-04-09
US20190321341A1 (en) 2019-10-24
US20220241253A1 (en) 2022-08-04
WO2019195813A1 (en) 2019-10-10
CN112601524A (zh) 2021-04-02
AU2019249277A1 (en) 2020-10-22
JP2021521103A (ja) 2021-08-26
EP3761979A1 (en) 2021-01-13
IL277805A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US20250127712A1 (en) Compositions and methods for the treatment of opioid overdose
CN101626766B (zh) 药用组合物的改进和与药用组合物相关的改进
JP4898073B2 (ja) 鼻内投与用フェンタニル組成物
TWI486161B (zh) 含那若松（ｎａｌｏｘｏｎｅ）的鼻內藥物劑型
US20250302771A1 (en) Treatment of opioid use disorder, opioid withdrawal symptoms and chronic pain
US20220241253A1 (en) Use of gaboxadol in the treatment of substance use disorders
HK1231370A1 (zh) 鼻用药物产品及其使用方法
WO2020097279A1 (en) Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
US20260021038A1 (en) Compositions and Methods for the Treatment of Opioid Overdose
AU2019253577B2 (en) Oxytocin compositions and methods of use
KR20200022026A (ko) 치료 방법 및 이의 약형
HK40050846A (en) Use of gaboxadol in the treatment of substance use disorders

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250923

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230